# Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

> **NCT02733445** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 2650 (actual)

## Conditions studied

- Chronic Myeloid Leukemia (CML)

## Interventions

- **DRUG:** dasatinib
- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT02733445
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 2650 (ACTUAL)
- **Last updated:** 2016-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733445, "Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02733445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*